Exosome Tracer Complex With Gallium-67/68 Radionuclide and DOTA Chelating Agent
Summary
The USPTO published patent application US20260108642A1 on April 23, 2026, disclosing an exosome-based tracer complex incorporating gallium-67 or gallium-68 radionuclides chelated to a bifunctional chelating agent, preferably DOTA. The application was originally filed on December 5, 2024, under application number 18969548, with six inventors named. The invention is classified under A61P 25/28 (CNS disorders) and A61P 35/04 (cancer metastasis), suggesting potential diagnostic imaging applications for neurological conditions and oncology.
“The complex comprises an exosome, a bifunctional chelating agent coupled to the exosome, and a radionuclide gallium-67 or gallium-68 embedded on the bifunctional chelating agent.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
The USPTO published patent application US20260108642A1 disclosing a novel exosome-based tracer complex for diagnostic imaging applications. The invention comprises an exosome coupled to a bifunctional chelating agent—preferably 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)—with gallium-67 or gallium-68 radionuclides embedded on the chelating agent. The patent covers uses in neurological conditions (A61P 25/28) and cancer metastasis imaging (A61P 35/04). Affected parties include pharmaceutical and biotechnology companies developing exosome-based therapeutics or diagnostic imaging agents, as well as medical device manufacturers working in nuclear medicine diagnostics. This publication represents a prior art event that may affect freedom-to-operate analyses for competing exosome or radiopharmaceutical programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USE OF EXOSOME, COMPLEX COMPRISING EXOSOME, TRACER, AND PREPARATION METHOD THEREOF
Application US20260108642A1 Kind: A1 Apr 23, 2026
Inventors
MEI-HUI WANG, Kai-Hung Cheng, Chen-Hsin Chan, Chung-Li Ho, Hung-Wen Yu, Yi-Shan Chen
Abstract
Provided herein are use of an exosome, a complex comprising an exosome, a tracer, and a preparation method and use thereof. The complex comprises an exosome, a bifunctional chelating agent coupled to the exosome, and a radionuclide gallium-67 or gallium-68 embedded on the bifunctional chelating agent. In a preferred implementation, the bifunctional chelating agent comprises 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).
CPC Classifications
A61K 51/1203 A61K 51/0482 A61P 25/28 A61P 35/04 A61K 2121/00 A61K 2123/00 B82Y 5/00
Filing Date
2024-12-05
Application No.
18969548
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.